ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
November 17 2017 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company
developing new medications targeted at inflammatory and autoimmune
diseases and cancer, today announced that Thomas J. Schall, Ph.D.,
President and Chief Executive Officer, will participate in a
fireside chat at the Piper Jaffray 29th Annual Healthcare
Conference on Tuesday, November 28, 2017 at 11:30am ET. The
conference will be held at the Lotte New York Palace Hotel in New
York, NY.
A live audio webcast of the fireside chat discussion can be
accessed through the Investors section of the Company's website at
www.ChemoCentryx.com. A replay of the webcast will be available on
the Company's website for two weeks following the live
discussion.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally-administered
therapies. ChemoCentryx is currently focusing on its late stage
drug candidates for patients with rare kidney diseases, avacopan
(CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(AAV). In clinical studies to date, avacopan was shown to be safe,
well tolerated and provided effective control of the disease while
allowing elimination of high-dose steroids, part of the current
standard of care. Avacopan is also being developed in patients with
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome
(aHUS). The U.S. Food and Drug Administration has granted avacopan
orphan-drug designation for AAV, C3G and aHUS. The European
Commission has granted orphan medicinal product designation for
avacopan for the treatment of two forms of AAV: microscopic
polyangiitis and granulomatosis with polyangiitis (formerly known
as Wegener's granulomatosis), as well as for C3G. Avacopan was also
granted access to the European Medicines Agency's (EMA) PRIority
MEdicines (PRIME) initiative, which supports accelerated assessment
of investigational therapies addressing unmet medical need.
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts:
Susan M.
Kanaya
Executive Vice President, Finance and Chief Financial and
Administrative
Officer
investor@chemocentryx.com
Media:Stephanie Tomei408.234.1279tomei.stephanie@gmail.com
Investors:Burns McClellan, Inc. Steve
Klass212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024